PDF
(Download)
|
- Ginkgo (Ginkgo biloba)
- Acute Ischemic Stroke
- Neuroprotection
|
Date:
01-31-2014 | HC# 011451-489
|
Re: Ginkgo Improves Outcomes in Patients following Acute Ischemic Stroke
Oskouei
DS, Rikhtegar R, Hashemilar M, et al. The effect of Ginkgo biloba on functional outcome of patients with acute ischemic
stroke: a double-blind, placebo-controlled, randomized clinical trial. J Stroke Cerebrovasc Dis. November 2013;22(8):e557-e563.
Acute
ischemic stroke (AIS) accounts for 88% of stroke events. During AIS, neurons
die in part due to oxidative stress. Preclinical studies show that ginkgo (Ginkgo biloba) provides neuroprotection.
Clinical studies are needed to evaluate the effect of ginkgo in the management
of AIS. The purpose of this prospective, randomized, placebo-controlled
clinical trial was to assess the effect of ginkgo on functional outcomes of
patients with AIS.
Consecutive
patients (n = 102) with AIS involving the anterior cerebral circulation, who
were ≥ 45 years old, and admitted to Tabriz Imam Reza and Razi Hospitals, East
Azerbaijan province, Iran, between January 2009 and September 2011 were
included in this study. The exclusion criteria were as follows: anticoagulant
therapy; patients with chronic kidney, hepatic, and hematologic diseases;
pregnant or lactating women; and having a profound loss of consciousness (i.e.,
stupor and coma). Only patients with involvement of the anterior circulation were
included, because patients with posterior circulation insufficiency receive anticoagulation
agents which should not be used simultaneously with ginkgo. For 4 months,
patients received either placebo or 120 mg/day ginkgo (Gol-Darou Company;
Isfahan, Iran). The clinical severity and functional ability of patients were
assessed with the National Institutes of Health Stroke Scale (NIHSS). The
primary outcome measure was a 50% reduction in the 4-month NIHSS score compared
with baseline. Blood was drawn to measure fasting blood glucose, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total
cholesterol, triglyceride, prothrombin time, international normalized ratio, and
partial thromboplastin time at admission.
There
were no significant differences between age and sex distribution or for any of
the biochemical or hematological parameters. Both treatment groups had a
similar mean difference in NIHSS score between baseline and 4-month follow-up,
and between baseline and hospital discharge. A total of 58.6% of ginkgo-treated
patients had a 50% improvement in outcomes, statistically significant compared
with 18.5% of placebo-treated patients (P < 0.05). A total of 81.6% of
ginkgo-treated patients had ≥ 1 stage improvement in stroke severity (i.e.,
from moderate to mild), and 68.8% of placebo-treated patients had ≥ 1 stage
improvement in stroke severity, a difference that was not statistically
significant (P > 0.05). When adjusting for age and gender, there was a
significant improvement in NIHSS scores in the ginkgo group compared with the
placebo group (P < 0.05). Adverse events were not reported.
The
authors conclude that ginkgo can improve functional recovery in patients with
AIS, and ginkgo may be providing neuroprotection. The authors state that ginkgo
should be recommended after AIS; although they acknowledge that additional
research is needed to confirm the findings. Of note, a higher daily dose (e.g.,
240 mg) might be more effective, as in the treatment of cognitive impairment
and dementia. Treatment for patients with AIS is limited because most
pharmaceuticals must be administered as soon as possible for the most robust
effect. The authors did not discuss the data in relation to when treatment was
initiated. It would be interesting and of medical value to determine whether
ginkgo was effective after a delay in seeking treatment. An important
limitation of the study is that the authors did not discuss time of treatment
initiation. For the placebo group to be a true control, both groups would need
to have a similar time of treatment initiation. In addition, aside from noting
the manufacturer that produced the 40 mg ginkgo tablets, the preparation was
not characterized regarding its processing or content.
—Heather
S. Oliff, PhD
Peer
Review Comment:
There
are some quality of reporting issues with this paper. It is not stated who
carried out the randomization procedure, whether the analysis was per protocol
or intention-to-treat, or if any check on blinding was carried out at the end
of the study (i.e., asking patients if they thought they had received placebo
or verum). The authors could have used the CONSORT (Consolidated Standards of
Reporting Trials) herbal guidelines as a basis for reporting details of the
herbal intervention as well as the standard CONSORT statement for reporting of randomized,
controlled trials (RCTs) in general. It is quite remarkable that this paper
does not discuss monitoring of, or provide any data on, adverse events. Since
the authors state that "G. biloba
is recommended after AIS," some consideration of safety aspects, including
any potential for interactions with conventional medicines used, should have
been included.
A related point about quality of reporting of this
trial with respect to the "herbal" elements is that ginkgo is
frequently misspelt in the paper (as Gingko), including in the keywords.
|